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Recent studies reported a broad but selective antiviral activity of 25-hydroxycholesterol (25HC) against
enveloped viruses, being apparently inactive against non-enveloped viruses. Here we show that 25HC is
endowed with a marked antiviral activity against three pathogenic non-enveloped viruses, i.e. human
papillomavirus-16 (HPV-16), human rotavirus (HRoV), and human rhinovirus (HRhV), thus significantly
expanding its broad antiviral spectrum, so far recognized to be limited to viruses with envelope. Moreover,
here we disclose the remarkable antiviral activity of another oxysterol of physiological origin, i.e.
27-hydroxycholesterol (27HC), against HPV-16, HRoV and HRhV.We have also identified a much weaker
antiviral activity of other oxysterols of pathophysiological relevance, i.e 7a-hydroxycholesterol,
7b-hydroxycholesterol, and 7-ketocholesterol. These findings suggest that appropriate modulation of
endogenous production of oxysterols might be a primary host strategy to counteract a broad panel of viral
infections. Moreover, 25HC and 27HC could be considered for new therapeutic strategies against HPV-16,
HRoV and HRhV.
T
he oxysterols are a family of 27-carbonmolecules originating from cholesterol oxidation by either enzymatic
or non-enzymatic mechanisms. Compared to cholesterol, they contain an additional hydroxy, epoxide or
ketone group in the sterol nucleus, and/or a hydroxyl group in the side chain1,2. Various oxysterols of
enzymatic origin have long been studied, thanks to the physiological roles they play, for instance, in bile acid
synthesis, steroid hormone biosynthesis, sterol transport, and gene regulation. In particular, oxysterols like 22-R-
hydroxycholesterol (22OHC), 25-hydroxycholesterol (25HC), and 27-hydroxycholesterol (27HC)were shown to
be very good ligands of Liver X Receptors (LXRs)3, nuclear receptors that function as master transcription factors
in cell metabolism and proliferation, as well as in inflammation and immunity4,5. More recently, a still-growing
body of evidence has supported the potential contribution of certain physiologically-relevant oxysterols to the
pathogenesis and progression of major human chronic inflammation-associated diseases6 but also their involve-
ment in innate and adaptive immunity7.
New and original emphasis on the beneficial effects of at least certain oxysterols has now been given by the
demonstration that 25HC displays marked broad antiviral properties8,9: added at lowmicromolar concentrations
(1–10 mM) to cultivated cells, this oxysterol was shown to inhibit the entry of vescicular stomatitis virus (VSV)
and human immunodeficiency virus (HIV), as well as cell membrane fusion. It also inhibited the replication of
several other DNA and RNA viruses, all having as common feature an outer lipid envelope covering their protein
capsid8. 25HC is reported to exert antiviral activity only against enveloped viruses, and not against non-enveloped
viruses, a conclusion that was drawn from its lack of antiviral effect when added to human embryonic kidney cells
infected with adenovirus Ad5 or Ad19, a non-enveloped virus. Moreover, in the same report, antiviral properties
were shown only to be exerted by 25HC, and not by the two other side chain cholesterol oxidation products tested,
i.e. 22(R)hydroxycholesterol and 22(S)hydroxycholesterol8. The few studies on the antiviral effect of oxysterols
that have appeared to date have focused on enveloped viruses, and essentially on the antiviral activity of 25HC, the
gene coding for 25-hydroxycholesterol oxidase having been shown to bemodulated by type I interferons10 and by
lipopolysaccharides11. HCV replication in Huh7 hepatoma cells was significantly reduced when cells were
transfected with the oxysterol-binding protein related-protein 4 (ORP-4), then incubated with 25HC12.
Likewise, HBV infection of HepG2 cells transfected with the sodium taurocholate cotransporting polypeptide
(NTCP) membrane transporter was significantly counteracted by cell preincubation with 25HC, a treatment that
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interfered with viral entry13. In the model of HBV infected HepG2
cells, 22-S-hydroxycholesterol and 7b-hydroxycholesterol also
appeared to exert significant antiviral effect13.
In the light of this interesting emerging evidence of 25HC’s anti-
viral properties, and of the intriguing fact that the effect apparently
selectively targets enveloped viruses, it was deemed useful to address
this hot topic via an additional and wider approach, i) by focusing for
the first time on a panel of non-enveloped viruses, consisting of
major human pathogens, namely human papillomavirus-16 (HPV-
16), the etiologic agent of cervical carcinoma and other human
malignacies14, human rotavirus (HRoV), the etiologic agent of severe
gastroenteritis in infants15 and the human rhinovirus (HRhV), the
major etiologic agent of the common cold, the most frequent infec-
tious disease in humans16, and ii) testing the antiviral effect not only
of 25HC but also of the whole panel of the most widely found oxy-
sterols in human blood17, namely 7-ketocholesterol (7kC), 7a-hydro-
xycholesterol (7aHC), 7b-hydroxycholesterol (7bHC) and, above
all, 27HC, another oxysterol of enzymatic origin like 25HCwith high
pathophysiological impact, especially on innate and adaptive
immunity and inflammation18.
The results demonstrate that 25HC and 27HC exert a marked
inhibitory activity against HPV-16, HRoV and HRhV.
Results and Discussion
The picture emerging from reported studies8,9 was that 25HC might
be a broad-spectrum but selective inhibitor of enveloped viruses,
being apparently inactive against non-enveloped viruses. To explore
whether this really was the case, this study investigated the antiviral
activity of 25HC against HPV-16, HRoV, and HRhV, which were
selected for their severe impact on human health, and as representa-
tives of three families of non-enveloped viruses: Papillomaviridae,
Reoviridae, and Picornaviridae, each containing significant human
pathogens14–16. Moreover, the most widely found oxysterols in
human blood, all but one not previously tested for their antiviral
potential (i.e. 27HC, 7aHC, 7bHC, 7kC) were included in this study.
A first set of experiments was performed by pretreating the cells
with oxysterols for several hours before infection, as reported by Su-
Yang Liu, (2013)8, in order to obtain data comparable to those
reported in the literature. The results, shown in Figure 1A, dem-
onstrate that neither 25HC nor the other tested oxysterols affected
the infectivity of Ad5. These results confirmed those of the other
study9. But, expanding this investigation to include other non-
enveloped viruses, it was found that not only 25HC but also 27HC
exerted a marked antiviral activity against HPV-16, HRoV and
HRhV (Fig. 1, panel B, C, and D respectively) with EC50 values in
the high nanomolar range for HRoV and HRhV, and in the low
micromolar range for HPV-16 (Table 1, EC50 pretreatment column).
Unlike these two side-chain cholesterol oxidation products, 7aHC,
7bHC and 7kC were found to be inactive against HPV-16 and
HRhV, and barely active against HRoV. To exclude the possibility
that the antiviral activity might depend on oxysterols’ cytotoxic
effects, a cell viability assay was performed on uninfected cells, chal-
lenged with the tested molecules under the same conditions as the
antiviral assays. As shown in Table 1, neither 25HC nor 27HC exhib-
ited any toxic effects in the range of concentrations employed (up to
150 mM) as is shown by the non-determinable 50% cytotoxic con-
centrations (CC50) and the favorable selectivity indexes (SI).
Interestingly, when oxysterols were added to the cells at the same
time of the virus inoculum (time zero) a full absence of any antiviral
activity at all the tested concentrations appeared evident (Table 1).
This finding ruled out a direct interference with virus-receptor inter-
action exerted by the oxysterols themselves. Moreover, it suggested
that the antiviral activity was not mediated through a direct inactiva-
tion of viral particles by 25HC or 27HC. To verify this hypothesis, we
performed a viral inactivation assay as described in the Methods
section.
As shown in Table 2, the virus titers of samples treated with oxy-
sterols did not significantly differ from those determined in samples
exposed to the solvent only (i.e. ethanol) indicating that these mole-
cules did not exert any direct effect at all on viral particles. Taken
together, the results reported in Table 1 and Table 2 show that 25HC
and 27HC exert their antiviral activity by targeting intracellular
events involved in essential steps of the HPV-16, HRoV and
HRhV replicative cycles. A multidisciplinary research approach is
currently in progress aiming to elucidate the cellular effectors and/or
the viral targets of 25HC and 27HC.
The antiviral activity of oxysterols was further investigated via a
virus yield assay, a test condition that reflects more closely an
ongoing productive infection in vivo being a stringent assay that
allows multiple cycles of viral replication to occur before measuring
the production of infectious viruses. Only those viruses that were
susceptible to oxysterol inhibition in the previous experiments were
tested (i.e. HRoV and HRhV); HPV-16 was not tested, since pseu-
dovirus particles are unable to undergo a productive replicative cycle.
In this set of experiments, cells were treated at a fixed oxysterol
concentration (5 mM) after viral inoculum. The results, in
Figure 2A, show that treatment with 25HC determined a significant
(0.001 , p , 0.01) reduction in HRoV yield, while 27HC exerted
modest, yet statistically significant, antiviral activity. Of note, both
25HC and 27HC completely abolished the replication of HRhV
(Fig. 2 B). Moreover, under these experimental conditions, 7aHC,
7bHC and 7kC where slightly active against HRoV and HRhV.
Taken together, these findings first of all extend the antiviral activity
of 25HC to a panel of widespread non-enveloped viral pathogens,
and demonstrate that the spectrum of antiviral activity of oxysterols
could be broader than believed thus far. Moreover, this study dis-
closes the antiviral potential of one of themost common oxysterols in
the peripheral blood of healthy individuals, namely 27HC13, and,
although to a lesser extent, of 7aHC, 7bHC and 7kC, also consis-
tently detectable in human blood13.
Following the demonstration of antiviral properties of 25HC
against a broad group of enveloped viruses8,12,13, the inhibition
reported here, of non-enveloped viruses of primary global import-
ance, by a panel of physiologically-relevant oxysterols, provides fresh
and amplified support to the hypothesis that endogenous production
of oxysterolsmight be a host strategy to counteract viral infections. In
this connection, it is noteworthy that 27HC is generated by choles-
terol 27-hydroxylase (CYP27A1), a mitochondrial cytochrome P450
oxidase present in various tissues and cells, particularly in the liver
and macrophages19.
The EC50 values of 25HC and 27HC, calculated for HRoV, HRhV
and HPV-16 (Table 1) are certainly higher than those found in the
blood of healthy individuals, which are in the low nanomolar range17.
However, they are relatively low compared to those detectable in
inflammation-driven chronic disease processes, e.g. atheroscler-
osis20,21. This means that, theoretically, appropriate stimulation of
their enzymatic production might be achievable, and in the light of
the apparent absence of direct cytotoxic effects could be attempted
(Table 1). How immune cells likely modulate the endogenous pro-
duction of oxysterols remains entirely unknown, but will be a fascin-
ating process to investigate. Overall, the therapeutic application of
the antiviral properties of the panel of oxysterols studied here does
not appear too distant a possibility.
Methods
Cell lines and viruses. African green monkey kidney epithelial (MA104) cells and
human epithelial adenocarcinomaHeLa cells (ATCCH CCL-2TM) were propagated in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco-BRL, Gaithersburg, MD)
supplemented with heat-inactivated 10% fetal bovine serum (FBS) (Gibco-BRL) and
1% antibiotic-antimycotic solution (Zell Shield, Minerva Biolabs GmbH, Berlin,
Germany), at 37uC in an atmosphere of 5% of CO2. The 293TT cell line, derived from
human embryonic kidney cells transformed with the simian virus 40 (SV40) large T
antigen, was cultured as monolayer in medium in DMEM supplemented with heat-
inactivated 10% FBS and Glutamax-I (Invitrogen, Carlsbad, CA) and nonessential
www.nature.com/scientificreports
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amino acids. 293TT cells enable high levels of protein to be expressed by vectors
containing the SV40 origin, due to overreplication of the expression plasmid.
Human rotavirus strain Wa (ATCCH VR-2018) was purchased from ATCC; the
virus was activated with 5 mg/ml of porcine pancreatic trypsin type IX (Sigma, St.
Louis, Mo.) for 30 minutes at 37uC, and propagated in MA104 cells using DMEM
containing 0.5 mg of trypsin per ml as described elsewhere22.
Human rhinovirus 1A (ATCCH VR-1559) was purchased from ATCC. The virus
was propagated in HeLa cells, at 33uC, in a humidified 5% CO2 incubator. When the
full cytopathic effect (CPE) developed, cells and supernatants were harvested, pooled,
frozen and thawed three times, clarified and aliquoted. Viruses were stored at270uC.
Rhinovirus titers were determined by the standard plaque method. Briefly, HeLa cells
were seeded 2 days before infection in 96-well plates, reaching 60%–70% confluence
at the time of infection. The viral suspension was serially diluted in DMEM supple-
mented with 2% fetal bovine serum and inoculated; the infected wells were incubated
at 33uC for 1 hour, allowing viruses to attach and enter the cells. After this time, cells
were washed with medium, and overlaid with a 151 combination of 1.6% SeaPlaque
Agarose (BioWhittaker Molecular Applications) and 2 3 DMEM medium (Gibco
BRL) as described elsewhere23. The plates were incubated at 33uC for 3 days. After
incubation, the plates were fixed and stained as described elsewhere23, the number of
plaques formed was counted; viral titers were expressed in terms of plaque forming
units per ml (PFU/ml).
Adenovirus 5 encoding GFP (GFP-Ad5) has a E1/E3 deletion that in HeLa cells
results in a replication deficiency and it was purchased from Vector Biolabs
(Philadelphia, PA, USA). The titer was 1.5 3 1011 PFU/ml in PBS with 5% Glycerol.
The virus was stored at 280uC until use.
HPV PsV production. Plasmids and 293TT cells used for pseudovirus (PsV)
production were kindly provided by John Schiller (National Cancer Institute,
Bethesda, MD). Detailed protocols and plasmid maps for this study can be seen at
http://home.ccr.cancer.gov/lco/default.asp. HPV-16 PsVs were produced by
methods described elsewhere. Briefly, 293TT cells were cotransfected with a
bicistronic plasmid (p16 shell) expressing the papillomavirus major andminor capsid
proteins (L1 and L2, respectively), together with a reporter plasmid expressing GFP.
Capsids were allowed to mature overnight in cell lysate; the clarified supernatant was
Figure 1 | Antiviral activity of oxysterols against Ad5 (A), HPV16 (PsV) (B), HRoV (C) and HRhV (D). Cells were treated for 16 h (Ad5 or HPV-16
assays) or for 20 h (HRoV and HRhV assays) with increasing concentrations of oxysterols, and then infected. Viral infections were detected as
described in the Methods section. The percentage infection was calculated by comparing treated and untreated wells. The results are means and SEM for
triplicates.
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then loaded on top of a density gradient of 27 to 33 to 39% Optiprep (Sigma-Aldrich,
St. Louis, MO) at room temperature for 3 h. The material was centrifuged at
28000 rpm for 16 h at 4uC in an SW41.1 rotor (BeckmanCoulter, Inc., Fullerton, CA)
and then collected by bottom puncture of the tubes. Fractions were inspected for
purity in 10% sodium dodecyl sulfate (SDS)–Tris–glycine gels, titrated on 293TT cells
to test for infectivity by GFP detection, and then pooled and frozen at 280uC until
needed. The L1 protein content of PsV stocks was determined by comparison with
bovine serum albumin standards in Coomassie-stained SDS-polyacrylamide gels.
Reagents. 25-, 27- 7a-, 7b-hydroxycholesterol (25HC, 27HC, 7aHC, 7bHC) or 7k-
cholesterol (7kC) (SIGMA) were dissolved in ethanol at concentrations ranging from
2.75 mM to 3 mM.
Cell viability assay.Cells were seeded at a density of 53 103/well in 96-well plates and
treated the following next day with serially-diluted oxysterols (25HC, 27HC, 7aHC,
7bHCor 7kC) to generate dose-response curves. After 24 or 120 hours of incubation,
cell viability was determined using the CellTiter 96 Proliferation Assay Kit (Promega,
Madison, WI, USA), and following the manufacturer’s instructions. Absorbances
were measured using a Microplate Reader (Model 680, BIORAD) at 490 nm. The
effect of oxysterols at different concentrations on cell viability was expressed as a
percentage, by comparing absorbances of treated samples with those of the respective
controls.
HPV inhibition assay. HeLa cells were seeded 24 h in advance in 96-well tissue-
culture-treated flat-bottom plates, at a density of 8,000 cells/well in 100 ml. The
following day, cells were treated with serial dilutions of compounds. After 16 hours,
compounds were removed and diluted PsV stocks (approximately 1 ng/ml L1) were
added to the cells (this condition is indicated as ‘‘pretreatment’’ in Table 1). Alternatively
the serial dilutions of oxysterols were added at the same time of the PsVs inoculum (this
condition is indicated as ‘‘time zero’’ in Table 1). After 72 h at 37uC, the GFP-expressing
infected cells were observed under an inverted Zeiss LSM510 fluorescence microscope
(Zeiss, Oberkochen, Germany) and the percentages of infection were calculated by
comparing GFP positive cells in treated and untreated wells.
Rotavirus inhibition assays. The oxysterols’ antiviral efficacy was determined by the
focus reduction assay and the viral yield reduction assay. Assays of oxysterol
Table 1 | Antiviral activities of oxysterols
Oxysterols Virus EC50* time zero (mM) EC50* (95% C.I.)** 16/20 h pretreatment (mM) CC50*** (mM) SI****
25HC Ad5 n.a. n.a. .150 n.a.
HPV-16 n.a. 2.20 (1.61–2.99) .150 .68.18
HRoV n.a. 0.05 (0.03–0.10) .150 .3000
HRhV n.a. 0.29 (0.18–0.44) .150 .517.2
27HC Ad5 n.a. n.a. .150 n.a.
HPV-16 n.a. 9.34 (5.07–17.19) .150 .16.06
HRoV n.a. 0.25 (0.19–0.33) .150 .600
HRhV n.a. 0.62 (0.43–0.89) .150 .241.9
7aHC Ad5 n.a. n.a. .150 n.a.
HPV-16 n.a. n.a .150 n.a.
HRoV n.a. n.a. .150 n.a.
HRhV n.a. n.a .150 n.a.
7bHC Ad5 n.a. n.a. 35.93 n.a.
HPV-16 n.a. n.a. 35.93 n.a.
HRoV n.a. n.a. 71.84 n.a.
HRhV n.a. n.a. 35.93 n.a.
7kC Ad5 n.a. n.a. 82.22 n.a.
HPV-16 n.a. n.a. 82.22 n.a.
HRoV n.a. n.a. 40.31 n.a.
HRhV n.a. n.a. 82.22 n.a.
*EC50 half maximal effective concentration.
**C.I. confidence interval.
***CC50 half maximal cytotoxic concentration.
****SI selectivity index.
n.a. not assessable.
Table 2 | Virus inactivation assay
Incubation time Virus Incubation condition Viral titer* 6 SEM **
0 h HPV-16 Ethanol 3.2 3 106 6 0.4 3 106
25HC 3.4 3 106 6 0.4 3 106
27HC 3.3 3 106 6 0.1 3 106
HRoV Ethanol 5.8 3 105 6 0.7 3 105
25HC 5.3 3 105 6 0.4 3 105
27HC 5.9 3 105 6 0.7 3 105
HRhV Ethanol 1.5 3 105 6 0.2 3 105
25HC 2.1 3 105 6 0.1 3 105
27HC 2.3 3 105 6 0.3 3 105
2 h HPV-16 Ethanol 2.0 3 105 6 0.1 3 105
25HC 2.5 3 105 6 0.1 3 105
27HC 2.3 3 105 6 0.2 3 105
HRoV Ethanol 4.5 3 105 6 0.2 3 105
25HC 4.2 3 105 6 0.1 3 105
27HC 4.9 3 105 6 0.2 3 105
HRhV Ethanol 9.4 3 104 6 0.6 3 104
25HC 10.7 3 104 6 0.7 3 104
27HC 9.2 3 104 6 0.9 3 104
*viral titer is expressed as FFU/ml for HPV-16 and HRoV and in PFU/ml for HRhV.
**SEM: standard error of the mean.
www.nature.com/scientificreports
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inhibition of rotavirus infectivity were carried out with confluent MA104 cell
monolayers plated in 96-well trays, as described elsewhere24. Cells were treated for
20 h at 37uCwith 25HC, 27HC, 7aHC, 7bHCor 7kC, at concentrations ranging from
0.07 to 16.7 mM. Control samples were prepared by treating cells with culture
medium supplemented with equal volumes of ethanol. Cells were later washed with
medium, and rotavirus infection was performed at a multiplicity of infection (MOI)
of 0.02 PFU/cell (this condition is indicated as ‘‘pretreatment’’ in Table 1).
Alternatively the serial dilutions of oxysterols were added at the same time of HRoV
inoculum (this condition is indicated as ‘‘time zero’’ in Table 1). After infection, cells
were washed with medium and incubated at 37uC in a humidified incubator in 5%
(vol/vol) CO2–95% (vol/vol) air. After 16 hours, infected cells were fixed with cold
acetone-methanol (50550), and viral titers were determined by indirect
immunostaining.
To test the ability of oxysterols to inhibitmultiple cycles of viral replication,MA104
were plated in 24-well trays, until they reached confluence. Cells were washed with
medium and infected with trypsin-activated human rotavirus Wa (MOI 0.02). After
one hour, cells were washed and fresh medium, supplemented with 0.5 mg/ml of
porcine trypsin and containing different concentrations of oxysterols (ranging from
5.6 mM to 0.07 mM), was added. Infected cells and supernatants were harvested at
48 hours post-infection and titrated.
Rhinovirus inhibition assays. The oxysterols’ antiviral efficacy was determined by
the plaque reduction assay and viral yield reduction assay.
HeLa cells were first seeded (at 8 3 104 cells/well) in 24 well plates. The medium
was removed from the plates before treatment with different concentrations of 25HC,
27HC, 7aHC, 7bHC or 7kC (ranging from 0.07 mM to 5.6 mM). After 20 hours of
incubation (37uC, 5%CO2), medium with oxysterols was removed and infection was
performed with 200 ml/well containing ca. 30 PFU of a stock of human rhinovirus 1A
(this condition is indicated as ‘‘pretreatment’’ in Table 1). The infected cells were
incubated at 33uC for 1 h, allowing the virus to attach and enter the cells. Alternatively
the serial dilutions of oxysterols were added at the same time of HRhV inoculum (this
condition is indicated as ‘‘time zero’’ in Table 1). After incubation, cells were washed
with medium, and overlaid with a 151 combination of 1.6% SeaPlaque Agarose and
23DMEM. The plates were incubated at 33uC for 5 days. After incubation, the plates
were fixed with 7.5% formaldehyde (Fluka) and stained with crystal violet (Sigma, St.
Louis, Mo.). The number of plaques formed was counted.
To test the ability of oxysterols to inhibit multiple cycles of viral replication, HeLa
cells were plated in 24-well trays, until they reached confluence. Each well was
inoculated with 200 ml of a stock of human rhinovirus 1A containing ca. 30 PFU per
well and incubated for 1 hour. After incubation, cells were washed with medium, and
fresh medium was added (DMEM supplemented with 2% FBS) containing different
concentrations of oxysterols (ranging from 5.6 mM to 0.07 mM). Infected cells and
supernatants were harvested 5 days post-infection (when a complete CPE was vis-
ible), and titrated by using the plaque method as described above.
Ad5 inhibition assay. HeLa cells were seeded 24 h in advance in 96-well tissue-
culture-treated flat-bottom plates at a density of 8,000 cells/well in 100 ml. The
following day, cells were treated with serial dilutions of 25HC, 27OHC, 7aHC, 7bHC
or 7kC (ranging from 1.9 mM to 50 mM). After 16 hours, compounds were removed
and Ad5 (MOI 0.02 PFU/cell) was added to cells (this condition is indicated as
‘‘pretreatment’’ in Table 1). Alternatively the serial dilutions of oxysterols were added
at the same time of Ad5 inoculum (this condition is indicated as ‘‘time zero’’ in
Table 1). After 48 h at 37uC, the GFP-expressing infected cells were observed under
an inverted Zeiss LSM510 fluorescence microscope (Zeiss, Oberkochen, Germany)
and the percentages of infection were calculated comparing GFP positive cells in
treated and untreated wells.
Virus inactivation assays. Oxysterols at respective EC90 dose or equal volume of
ethanol were added to 10 ng ofHPV, 23 105 FFU/ml of HRoV or 23 105 PFU/ml of
HRhV and mixed in a total volume of 100 ml. The virus-compound mixtures were
incubated for 0 hours or 2 hours at 37uC then serially diluted to the non-inhibitory
concentration of test compound, and the residual viral infectivity was determined.
Statistical analysis. All data were generated from duplicate wells in at least three
independent experiments. Results of antiviral experiments are expressed as mean
percentages 6 standard error of the mean. Where possible, anti-viral effective
concentration (EC50) values were calculated by regression analysis, using the dose-
response curves generated from the experimental data, using GraphPad PRISM 5
(GraphPad Software, San Diego, California, U.S.A.). Viral yield reduction, in the
presence and absence of oxysterols, was compared by analysis of variance
(ANOVA) followed by a Bonferroni post-test, if P values showed significant
differences, using GraphPad Prism 5 (GraphPad Software, San Diego, California,
U.S.A.).
1. Schroepfer, G. J. Jr. Oxysterols: modulators of cholesterol metabolism and other
processes. Physiol. Rev. 80, 361–554 (2000).
2. Leonarduzzi, G., Chiarpotto, E., Biasi, F. & Poli, G. 4-Hydroxynonenal and
cholesterol oxidation products in atherosclerosis. Mol. Nutr. Food Res. 49,
1044–1049 (2005).
3. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R. & Mangelsdorf, D. J. An
oxysterol signaling pathway mediated by the nuclear receptor LXR alpha. Nature
383, 728–731 (1996).
4. Bensinger, S. J. & Tontonoz, P. Integration of metabolism and inflammation by
lipid-activated nuclear receptors. Nature 454, 470–477 (2008).
5. Bensinger, S. J. et al. LXR signaling couples sterol metabolism to proliferation in
the acquired immune response. Cell 134, 97–111 (2008).
6. Poli, G., Biasi, F. & Leonarduzzi, G. Oxysterols in the pathogenesis of major
chronic diseases. Redox Biol. 1, 125–130 (2013).
7. Cyster, J. G., Dang, E. V., Reboldi, A. & Yi, T. 25-Hydroxycholesterols in innate
and adaptive immunity. Nat. Rev. Immunol. 14, 731–743 (2014).
8. Liu, S.-Y. et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits
viral entry by production of 25-hydroxycholesterol. Immunity 38, 92–105 (2013).
9. Blanc, M. et al. The transcription factor STAT-1 couples macrophage synthesis of
25-hydroxycholesterol to the interferon antiviral response. Immunity. 38,
106–118 (2013).
Figure 2 | Virus yield reduction by oxysterols. Cells were infected with HRoV (A) or HRhV (B) and then treated with oxysterols (5 mM). When the
cytopathic effect involved the whole monolayer of untreated wells (i.e. 48 hours post infection for HRoV and 120 hours post infection for HRhV), cells
and supernatants were harvested together and titrated. The results are means and SEM for triplicates *** P , 0.001 **P , 0.01 * P , 0.05.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7487 | DOI: 10.1038/srep07487 5
10. Park, K. & Scott, A. L. Cholesterol 25-hydroxylase production by dendritic cells
and macrophages is regulated by type I interferons. J. Leukoc. Biol. 88, 1081–1087
(2010).
11. Diczfalusy, U. et al. Marked upregulation of cholesterol 25-hydroxylase
expression by lipopolysaccharide. J. Lipid Res. 50, 2258–2264 (2009).
12. Park, I. W. et al. Inhibition of HCV replication by oxysterol-binding protein-
related protein 4 (ORP4) through interaction with HCV NS5B and alteration of
lipid droplet formation. PLoS One 8, e75648 (2013).
13. Iwamoto, M. et al. Evaluation and identification of hepatitis B virus entry
inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
Biochem. Biophys. Res. Commun. 443, 808–813 (2013).
14.Howley, P.M.& Lowy,D. L. [Papillomaviruses] Fields virology, 5th edition [Knipe,
D. M. & Howley, P. M. (eds.)] [2299–2354] (Lippincott Williams and Wilkins,
Philadelphia, PA., 2006).
15. Estes, M. K. & Kapikian, A. Z. [Rotaviruses] Fields virology, 5th edition [Knipe,
D. M. & Howley, P. M. (eds.)] [1946–1974] (Lippincott Williams and Wilkins,
Philadelphia, PA., 2006).
16. Turner, R. B. & Couch, R. B. [Rhinoviruses] Fields virology, 5th edition [Knipe,
D. M. & Howley, P. M. (eds.)] [895–910] (Lippincott Williams and Wilkins,
Philadelphia, PA., 2006).
17. Honda, A. et al. Highly sensitive quantification of key regulatory oxysterols in
biological samples by LC–ESI-MS/MS. J. Lipid Res. 50, 350–357 (2009).
18. Spann, N. J. &Glass, C. K. Sterols and oxysterols in immune cell function. Nat.
Immunol. 14, 893–900 (2013).
19. Russell, D. W. Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta. 1529,
126–135 (2000).
20. Upston, J. M. et al. Disease stage-dependent accumulation of lipid and protein
oxidation products in human atherosclerosis. Am. J. Pathol. 160, 701–710 (2002).
21. Leonarduzzi, G., Poli, G., Sottero, B. & Biasi, F. Activation of the mitochondrial
pathway of apoptosis by oxysterols. Front. Biosci. 12, 791–799 (2007).
22. Coulson, B. S., Fowler, K. J., Bishop, R. F. &Cotton, R. G. Neutralizingmonoclonal
antibodies to human rotavirus and indications of antigenic drift among strains
from neonates. J. Virol. 54, 14–20 (1985).
23. Phipps, K. M., Martinez, A., Lu, J., Heinz, B. A. & Zhao, G. Small interfering RNA
molecules as potential anti-human rhinovirus agents: in vitro potency, specificity,
and mechanism. Antiviral Res. 61, 49–55 (2004).
24. Graham, K. L., Zeng, W., Takada, Y., Jackson, D. C. & Coulson, B. S. Effects on
rotavirus cell binding and infection of monomeric and polymeric peptides
containing alpha2beta1 and alphaxbeta2 integrin ligand sequences. J. Virol. 78,
11786–11797 (2004).
Acknowledgments
This work was supported by a grant from ‘‘Ricerca finanziata dall’Universita` degli Studi di
Torino (ex 60%), OxyVir project’’.
Author contributions
A.C. performed the antiviral assays against HRoV and HRhV and V.C. performed the
antiviral assays against HPV andAd5. A.C., V.C., G.P. andD.L. were involved in conception
of this work. M.D., F.B. and G.L. gave scientific advices and contributed to a deep
manuscript revision. D.L. supervised the work on the whole and provided laboratorymeans
for the antiviral assays. All authors contributed substantially to the present work then read
and approved the final manuscript.
Additional information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Civra, A. et al. Inhibition of pathogenic non-enveloped viruses by
25-hydroxycholesterol and 27-hydroxycholesterol. Sci. Rep. 4, 7487; DOI:10.1038/
srep07487 (2014).
This work is licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are included in the
article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need
to obtain permission from the license holder in order to reproduce thematerial. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7487 | DOI: 10.1038/srep07487 6
